menu
    • menu
    [{"orgOrder":0,"company":"Atalanta Therapeutics","sponsor":"EQT Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Series B Financing","leadProduct":"ATL-201","moa":"KCNT1","graph1":"Neurology","graph2":"IND Enabling","graph3":"Atalanta Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Atalanta Therapeutics \/ EQT Life Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Atalanta Therapeutics \/ EQT Life Sciences"},{"orgOrder":0,"company":"Atalanta Therapeutics","sponsor":"EQT Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Series B Financing","leadProduct":"ATL-201","moa":"KCNT1","graph1":"Neurology","graph2":"IND Enabling","graph3":"Atalanta Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Atalanta Therapeutics \/ EQT Life Sciences","highestDevelopmentStatusID":"5","companyTruncated":"Atalanta Therapeutics \/ EQT Life Sciences"},{"orgOrder":0,"company":"Atalanta Therapeutics","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"CIDEB","graph1":"Neurology","graph2":"Preclinical","graph3":"Atalanta Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Atalanta Therapeutics \/ Genentech","highestDevelopmentStatusID":"4","companyTruncated":"Atalanta Therapeutics \/ Genentech"}]

    Find Clinical Drug Pipeline Developments & Deals by Atalanta Therapeutics

    Menu

    Atalanta Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Atalanta Therapeutics

                            U.S.A arrow
                            BePharma
                            Not Confirmed

                            Atalanta Therapeutics

                            U.S.A arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ATL-201

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : EQT Life Sciences

                            Deal Size : $75.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            EQT Leads $75M Series B in Atalanta for Epilepsy, Huntington’s Therapies

                            Details : The proceeds will support Phase 1 clinical trials of the company's investigational RNAi therapies, including ATL-201 for KCNT1-related epilepsy and ATL-101 for Huntington's disease.

                            Product Name : ATL-201

                            Product Type : Oligonucleotide

                            Upfront Cash : Undisclosed

                            January 28, 2025

                            Lead Product(s) : ATL-201

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : EQT Life Sciences

                            Deal Size : $75.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Atalanta Therapeutics

                            U.S.A arrow
                            BePharma
                            Not Confirmed

                            Atalanta Therapeutics

                            U.S.A arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ATL-201

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : EQT Life Sciences

                            Deal Size : $97.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Atalanta Closes $97M Series B for Two RNAi CNS Therapies to Clinical Trials

                            Details : The financing aims to support clinical development of the company’s investigational RNAi therapy ATL-201 for treatment of KCNT1-related epilepsy.

                            Product Name : ATL-201

                            Product Type : Oligonucleotide

                            Upfront Cash : Undisclosed

                            January 28, 2025

                            Lead Product(s) : ATL-201

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : EQT Life Sciences

                            Deal Size : $97.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Atalanta Therapeutics

                            U.S.A arrow
                            BePharma
                            Not Confirmed

                            Atalanta Therapeutics

                            U.S.A arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Genentech

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Atalanta Therapeutics Announces Strategic Collaborations with Biogen, Genentech to Develop RNAi Therapeutics f...

                            Details : Atalanta will develop RNAi therapeutics for multiple targets, including HTT for Huntington’s disease, as well as additional unnamed CNS targets. The total funding at launch with the upfront payments from the partnerships and Series A financing is $110...

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Undisclosed

                            January 11, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Genentech

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth